Lisa Henderson

Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.

Pharm Exec editors share insights into what they've been working on this summer for the June, July, and August issues; plus a sneak peek into what's coming in September!

How one company’s cultural transformation aims to strengthen and empower its talent base.

Pharm Exec sits down with a pair of big pharma compliance leaders to discuss the strategic move to principles-based policies and the impact of other emerging forces influencing industry compliance practice.

Robert Finkel, the CEO of The FreshBlood Group talks with Pharm Exec editors about the positives and negatives of pharma’s marketing needs, the details and evolution around founding The FreshBlood Group, and how emerging pharma and biotech companies can budget in successful marketing.

Highlighting the biggest observations from this year's DIA Annual Meeting-topics likely to continue to dominate industry headlines for the foreseeable future.

Cameron Turtle, Chief Business Officer of Eidos Therapeutics, Robin Toft, Founder and CEO of The Toft Group Executive Search and Sabrina Johnson, President and CEO, Daré Bioscience join Pharm Exec editors to talk about the future of the life sciences executive.

Our latest rankings and report of the top 50 biopharma companies provides a nice springboard to the coverage we have in store for you in the year's second half.

Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.

In this executive roundtable, pharma and biotech finance leaders discuss the pace of digital technology adoption in accounting and reporting, and the growing recognition of data and analytics-over traditional numbers crunching-in delivering deeper business insights across the organization.

Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Bipharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.

With conference season in high gear, here's the lowdown on our content highlights so far from the event circuit and what to expect on horizon.

Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease.

The lifeblood of our coverage are the many interviews we conduct with industry executives-and the unique stories and insights they provide. Here, I highlight excerpts from a selection of wide-ranging conversations from the past year.

Providers of patient service solutions for pharma companies share insights on the nuances of the "consumer' connection and the shifts taking place in making patient-centric programs and tools more alive for patients.

That often-muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.

Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.

How innovation growth has upped the pressure on China to compete globally, forcing upgrades in regulatory, quality, and standards.

Pharm Exec profiles Dr. Xiaobin Wu, an accomplished leader in helming China operations at big pharmas such as Pfizer and Bayer, who believes his recent jump to biotech as GM of China and president of BeiGene will deliver his most lasting legacy.

Green-lighting China as our coverage focus in the February issue wasn't without conflict or hesitation, but as our reporting of the nation's biopharma landscape shows, perseverance and growth many times go hand-in-hand.

Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.

DIA Europe proves to have excellent timing to learn more about the latest developments in drug development, the current status of Brexit, the plans of the National regulators and EMA, on-going discussions on pan-European HTA, and the trends for 2019.

Highlighting a few topics that just missed the cut for our annual Industry Outlook-but are worth keeping a close eye on.

In pharma, there may be hope that companies' and the industry's ability to adapt to change may finally be catching up to the pace of new and intelligent uses of technology and clinical data.

As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?

As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.

Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Examining the rise and reach of biopharma in the key Northeast Corridor clusters of Boston, Philadelphia, and New Jersey.

With increasing responsibilities and decision-making post-discovery, the traditional label of “biotech” is changing.